A novel charge-enrichment and light-activated biomimetic nanosystem, designated as polyion liquid-bridged eosin Y (PIL-BEY), which offers a promising strategy for treating invasive metastatic tumors.
Abstract
Microbiome and transcriptome analyses revealed that Fusobacterium nucleatum (F.n) in clinical samples is associated with immune suppression and poor prognosis in triple-negative breast cancer spinal metastasis. However, its preferential localization in hypoxic tumor regions limits the efficacy of conventional antimicrobial therapies, which poorly penetrate solid tumors and function suboptimally under anaerobic conditions. Developing strategies that enable deep tumor penetration, eliminate anaerobic bacteria, and induce immunogenic cell death remains a major challenge. In this study, a novel charge-enrichment and light-activated biomimetic nanosystem, designated as polyion liquid-bridged eosin Y (PIL-BEY), was developed. On one hand, interionic hydrogen bonding and dynamic electrostatic interactions within polyionic liquids reduce the surface energy of the nanoprobe and synergistically remodel the dense tumor stromal microenvironment via photodynamic therapy, thereby facilitating the deep intratumoral penetration and accumulation of PIL-BEY. On the other hand, the novel photosensitizer BEY generates reactive oxygen species via electron transfer under hypoxic conditions, thereby effectively eradicating bacteria within hypoxic tumor regions. The resulting pathogen-associated molecular patterns, together with damage-associated molecular patterns, activate dendritic cells, promote cytotoxic T lymphocyte infiltration, trigger immunogenic cell death, and induce systemic antitumor immune responses with durable immune memory. This oxygen-independent, dual-functional nanoplatform offers a promising strategy for treating invasive metastatic tumors.
The intratumoral microbiota acts as a microbial immune checkpoint in colorectal cancer (CRC), yet current strategies either kill silently without immune activation or permit bacterial rebound through incomplete targeting. Here we report a bio-hybrid assembly designed to synchronize the eradication of CRC cells and thei...
Maliang Tao, Bin-Bin Wei, Yen-Yu Yang et al.· Advances in Materials· 0 citations
RELIB was developed to co-encapsulate the chemotherapeutic alkaloid Boldine and the near-infrared (NIR)-responsive photothermal dye IR775, enabling combined chemo-photothermal therapy with tunable therapeutic potential.
P. Ghosh, Sajmina Khatun, Sandip Das et al.· Translational Research: The...· 0 citations
This review systematically summarizes targeted nanomedicines constructed from mainstream carriers, including polymeric, metallic, and biomimetic nanoparticles, and discusses the future prospects of artificial intelligence-assisted optimization strategies for nanomedicine development.
Rui-Chao Li, Ze-Yuan Sun, Si-Nian Li et al.· International Journal of Pha...· 0 citations
Overall, this multifunctional nanomotor couples enhanced drug delivery with immune activation, effectively overcoming the structural and metabolic barriers of solid tumors, and represents a promising strategy for self-propelled therapeutic nanoparticles in cancer treatment.
Juan José Esteve-Moreno, Andrea Escudero, Francisco J. Hicke et al.· Journal of the American Chem...· 0 citations
Nanoparticles derived from various animals, plants, and microorganisms demonstrate potent application potential in the construction of functionalized pharmaceutic preparations, owing to their special in vivo behavioral and immune-stimulating effects. Yeast cell wall-derived nanoparticles (Ycws) can reverse the tumor im...
Yu-Ling Liu, Xue-Xue Liu, Chen-Xi Li et al.· Advanced Healthcare Material...· 0 citations
Nanomedicine is examined along three linked axes: stromal remodeling, hypoxia control, and photodynamic immune activation, which considers immune-active nanocarriers, such as STING agonists and mRNA vaccines, because stromal access and hypoxic stress shape their distribution.
M. Rauf, D. Lương, Farhan Shah et al.· Frontiers in Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.